Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.
Virtus KAR Health Sciences C RCGHX Fund Analysis
Morningstar’s Analysis RCGHX
Will RCGHX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar